Striving for Consensus on the Optimal Management of Metastatic Non-Small Cell Lung Cancer (Roundtable Audio Proceedings)


LungCancerSummit20/Roundtable

Roundtable Discussion with Drs Heymach, Horn, Johnson and Levy

Topic 1: Biomarker assessment for patients with metastatic non-small cell lung cancer (NSCLC)
Topic 2: Selection of first-line treatment for patients with metastatic NSCLC without actionable tumor mutations; role of immune checkpoint inhibitors
Topic 3: Case (Maria Picton, MD): A man in his mid-80s and previous smoker with metastatic adenocarcinoma of the lung and pleural effusion receives carboplatin/pemetrexed/pembrolizumab followed by maintenance pembrolizumab
Topic 4: Case (G Richard Polkinghorn, MD): A man in his early 50s with metastatic squamous cell carcinoma of the lung receives ramucirumab and docetaxel as second-line therapy
Topic 5: Use of immune checkpoint inhibitors for patients with a history of autoimmune disease
Topic 6: Case (Dr Polkinghorn): A woman in her early 60s and current smoker with multiple sclerosis and COPD receives nivolumab for metastatic NSCLC and attains a complete remission
Topic 7: Treatment of metastatic NSCLC with actionable tumor mutations, including ALK rearrangements
Topic 8: Case (Joseph T Martins, MD): A woman in her mid-70s and previous smoker with metastatic NSCLC and a MET mutation
Topic 9: Case (Margaret A Deutsch, MD): A man in his mid-60s, a never smoker, with metastatic adenocarcinoma of the lung and a KIF5B-RET fusion receives cabozantinib
Topic 10: Activity and tolerability of the selective RET inhibitors pralsetinib and selpercatinib; preliminary results from the Phase III ADAURA trial evaluating adjuvant osimertinib
Topic 11: Management of metastatic NSCLC in the era of COVID-19; preliminary results from the TERAVOLT registry on the impact of COVID-19 on the care of patients with lung cancer

Roundtable Discussion with Drs Borghaei, Brahmer, Garon and Govindan

Topic 12: Genomic profiling for patients with metastatic NSCLC; role of liquid biopsy
Topic 13: Therapeutic approach for patients with NSCLC with no targetable mutations
Topic 14: Case (Dr Deutsch): A woman in her late 60s with metastatic squamous cell carcinoma of the lung and a high PD-L1 tumor proportion score (TPS) of 60% initially treated with pembrolizumab monotherapy receives carboplatin/paclitaxel and maintenance pembrolizumab upon disease progression
Topic 15: Case (Dr Picton): A man in his mid-80s and previous smoker receives carboplatin/paclitaxel/pembrolizumab as first-line therapy for metastatic squamous cell carcinoma of the lung
Topic 16: Selection of second-line therapy for patients with metastatic nonsquamous NSCLC; benefits and risks with the addition of ramucirumab to docetaxel
Topic 17: Perspective on the use of bevacizumab or ramucirumab in combination with an immune checkpoint inhibitor and chemotherapy for metastatic NSCLC
Topic 18: Case (Dr Martins): A man in his early 70s and previous smoker with metastatic nonsquamous NSCLC develops diarrhea with bleeding after receiving first-line pembrolizumab
Topic 19: Screening and clinical care of patients with lung cancer during the COVID-19 pandemic
Topic 20: Case (Dr Picton): A woman in her early 50s with metastatic squamous NSCLC with a BRAF tumor mutation receives carboplatin/pemetrexed/pembrolizumab followed by maintenance pemetrexed/pembrolizumab and develops immune-related colitis
Topic 21: Management of metastatic NSCLC with targetable EGFR mutations
Topic 22: Case (Dr Deutsch): A woman in her late 40s and never smoker with metastatic adenocarcinoma of the lung with an EGFR tumor mutation develops a T790M mutation 2 years after treatment with erlotinib and bevacizumab on a clinical trial
 
CLINICAL INVESTIGATORS
 
Hossein Borghaei, DO, MS
Professor and Chief
Thoracic Oncology
The Gloria and Edmund M Dunn Chair
in Thoracic Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania
 
Julie R Brahmer, MD, MSc
Professor of Oncology
Director of the Upper Aerodigestive
Cancer Disease Program
Co-Director of the Cancer Immunology Program
Co-Director of the Upper Aerodigestive Cancer Program at
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Director of the Johns Hopkins Kimmel Cancer Center
on the Johns Hopkins Bayview Campus
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland
 
Edward B Garon, MD, MS
Associate Professor
Director
Thoracic Oncology Program
Director
Signal Transduction and Therapeutics Research Program
David Geffen School of Medicine at UCLA
Jonsson Comprehensive Cancer Center
Los Angeles, California
 
Ramaswamy Govindan, MD
Professor of Medicine
Director
Section of Oncology
Anheuser-Busch Endowed Chair in Medical Oncology
Washington University School of Medicine
St Louis, Missouri
 
John V Heymach, MD, PhD
Professor and Chair
Thoracic/Head and Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas
 
Leora Horn, MD, MSc
Ingram Associate Professor of Cancer Research
Director
Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt University Medical Center
Nashville, Tennessee
 
Melissa L Johnson, MD
Associate Director
Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee
 
Benjamin Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial
Medical Director, Thoracic Oncology Program
Washington, DC
 
GENERAL MEDICAL ONCOLOGISTS
 
Margaret A Deutsch, MD
Medical Oncologist
Duke Cancer Center Raleigh
Raleigh, North Carolina
 
Joseph T Martins, MD
Associate Professor of Medicine
UT Health East Texas HOPE Cancer Center
Tyler, Texas
 
Maria Picton, MD
Physicians East
Greenville, North Carolina
 
G Richard Polkinghorn, MD
Medical Director
Harold Alfond Center for Cancer Care
Augusta, Maine
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida